Cancer programme
Twelve cancers on rotation, two of them controls with known answers. The desk visits one every 10 minutes, coming back to each about every 2 hours, and carries what it learned into the next visit.
Melanoma · control case
Control case: INTerpath-001 / mRNA-4157 (V940) with pembrolizumab. The desk should reason toward kinase-independent immune priming via personalized neoantigens, and should reach that from the pack rather than from memory.
leadV940 plus pembrolizumab: personalized neoantigen immune priming in high-risk melanomaCLAMPED · claimed candidate
Intismeran autogene (V940) plus pembrolizumab operationalizes personalized mRNA neoantigen-driven T-cell priming with PD-1 checkpoint blockade in high-risk melanoma, without a kinase-pathway-targeted intervention in the V940 clinical regimen.
NEXT_QUERIES
> "mRNA-4157" melanoma pembrolizumab neoantigen-specific T cells
> "V940" melanoma pembrolizumab recurrence-free survival phase 3
> "intismeran autogene" melanoma biomarkers resistance
NSCLC
leadIntismeran autogene (V940) in phase 3 NSCLC
INTerpath-009 is a recruiting phase 3 NSCLC study of pembrolizumab with or without intismeran autogene (V940); the listed protocol includes platinum-doublet chemotherapy options and has primary completion projected for 2033.
leadImmunopeptidomics-guided neoantigen selection
In 24 NSCLC tumors, HLA-presentation-informed neoantigen selection produced functional responses in 5 of 6 tested patients; 9 of 70 putative neoantigens elicited strong responses.
leadAntigen-presentation competence as a vaccine-response gate
NSCLC immune resistance includes MHC-I, TAP2, B2M, and IFN/JAK-STAT defects, neoantigen loss, and immune-excluded states; these mechanisms constrain neoantigen-vaccine activity.
leadOperational constraints on personalized neoantigen mRNA vaccination
Personalized neoantigen mRNA vaccine implementation is constrained by manufacturing timelines, HLA diversity, tumor heterogeneity, and immune editing.
NEXT_QUERIES
> "intismeran autogene" OR V940 AND non-small cell lung cancer
> "personalized mRNA neoantigen vaccine" AND NSCLC AND clinical trial
> NSCLC neoantigen vaccine immunopeptidomics HLA presentation
Bladder
no entries yet · the desk has not banked a citation for this cancer
Pancreatic
no entries yet · the desk has not banked a citation for this cancer
Colorectal
no entries yet · the desk has not banked a citation for this cancer
Renal Cell
no entries yet · the desk has not banked a citation for this cancer
Head & Neck
no entries yet · the desk has not banked a citation for this cancer
Breast
no entries yet · the desk has not banked a citation for this cancer
Glioblastoma
no entries yet · the desk has not banked a citation for this cancer
Prostate
no entries yet · the desk has not banked a citation for this cancer
Ovarian
no entries yet · the desk has not banked a citation for this cancer
CML · control case
Control case: BCR-ABL1 fusion, imatinib class. Solved. Calibration — the desk should arrive at kinase inhibition from the target and trial evidence, and should NOT invent a personalized mRNA vaccine result that the pack does not contain. Reporting that there is no vaccine signal here is the correct answer.
no entries yet · the desk has not banked a citation for this cancer
NEXT_QUERIES
> "chronic myeloid leukemia" personalized mRNA neoantigen vaccine
> "CML" "neoantigen vaccine" mRNA
> "BCR-ABL" neoantigen mRNA vaccination
UNREVIEWED AI-generated hypothesis for human review. Promotion between LEAD, CANDIDATE and DOSSIER is enforced in code against verified citations — the model cannot promote itself.